BRISTOL MYERS SQUIBB CO

Form 4

March 03, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading HOOPER ANTHONY C Symbol **BRISTOL MYERS SQUIBB CO** [(BMY)](Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) **BRISTOL-MYERS SQUIBB** 03/01/2005 COMPANY, RT. 206 &

5. Relationship of Reporting Person(s) to Issuer

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

(Check all applicable)

10% Owner Director X_ Officer (give title Other (specify below) President US Pharmaceuticals

PROVINCELINE ROAD

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

PRINCETON, NJ 08540

Stock,

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 3. 2. Transaction Date 2A. Deemed 4. Securities 5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Security (Month/Day/Year) Execution Date, if TransactionAcquired (A) or (Instr. 3) Code Disposed of (D) Beneficially (D) or Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Indirect (I) Ownership (Instr. 4) Following (Instr. 4) Reported (A) Transaction(s) (Instr. 3 and 4) (D) Price Code V Amount Common Stock, 9,306 03/01/2005 A \$0 71,520 D A (1) \$0.10 par value Common By BMY Stock. Savings & $1,973.92^{(2)}$ I \$0.10 par Investment value Program Common 3,675 I By Spouse

Edgar Filing: BRISTOL MYERS SQUIBB CO - Form 4

\$0.10 par value

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Executive Option (right to buy)	\$ 25.45	03/01/2005		A	55,833	(3)	02/28/2015	Common Stock, \$0.10 par value	55,833

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

HOOPER ANTHONY C **BRISTOL-MYERS SQUIBB COMPANY** RT. 206 & PROVINCELINE ROAD PRINCETON, NJ 08540

President US Pharmaceuticals

Signatures

By: /s/ Sonia Vora, 03/03/2005 Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
- (2) Based on a plan statement as of the end of the most recent fiscal quarter.

Reporting Owners 2

Edgar Filing: BRISTOL MYERS SQUIBB CO - Form 4

Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option (3) grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.